Alnylam Pharma (ALNY) Misses Q3 EPS by 42c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $248.37 -1.3%
Revenue Growth %: +15.3%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: +15.3%
Financial Fact:
Total other income (expense): 2.32M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($2.43), $0.42 worse than the analyst estimate of ($2.01). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $18.23 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Cintas Corp. (CTAS) Tops Q1 EPS by 1c, Offers Guidance
- AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
